KLG Stock +78.58% In 3 Months Since We Picked KLG Stock +78.58% In 3 Months Since We Picked Unlock All Top Buy Picks

Range Low Price High Price Comment
30 days $0.87 $1.65 Friday, 26th Apr 2024 ADAP stock ended at $1.08. This is 1.42% more than the trading day before Thursday, 25th Apr 2024. During the day the stock fluctuated 5.83% from a day low at $1.03 to a day high of $1.09.
90 days $0.730 $2.05
52 weeks $0.420 $2.05

Historical Adaptimmune Therapeutics plc prices

Date Open High Low Close Volume
Sep 21, 2022 $1.48 $1.49 $1.36 $1.36 460 564
Sep 20, 2022 $1.49 $1.56 $1.48 $1.49 127 954
Sep 19, 2022 $1.55 $1.60 $1.36 $1.53 539 852
Sep 16, 2022 $1.62 $1.65 $1.50 $1.53 288 225
Sep 15, 2022 $1.65 $1.70 $1.62 $1.62 173 709
Sep 14, 2022 $1.78 $1.79 $1.62 $1.65 379 889
Sep 13, 2022 $1.87 $1.90 $1.76 $1.77 340 503
Sep 12, 2022 $1.90 $1.97 $1.85 $1.94 389 240
Sep 09, 2022 $2.12 $2.12 $1.89 $1.92 695 966
Sep 08, 2022 $1.86 $2.08 $1.85 $2.04 270 807
Sep 07, 2022 $1.93 $1.98 $1.83 $1.86 404 425
Sep 06, 2022 $2.06 $2.07 $1.93 $1.93 135 291
Sep 02, 2022 $1.95 $2.06 $1.93 $2.02 179 436
Sep 01, 2022 $2.00 $2.01 $1.90 $1.92 163 719
Aug 31, 2022 $1.94 $2.06 $1.93 $1.98 145 965
Aug 30, 2022 $2.05 $2.09 $1.92 $1.94 177 280
Aug 29, 2022 $2.05 $2.17 $2.03 $2.05 155 368
Aug 26, 2022 $2.21 $2.24 $2.05 $2.09 225 488
Aug 25, 2022 $2.27 $2.33 $2.18 $2.22 153 505
Aug 24, 2022 $2.18 $2.29 $2.17 $2.22 180 910
Aug 23, 2022 $2.10 $2.20 $2.07 $2.17 245 245
Aug 22, 2022 $2.10 $2.12 $2.04 $2.10 169 942
Aug 19, 2022 $2.07 $2.14 $2.07 $2.11 142 109
Aug 18, 2022 $2.12 $2.13 $2.00 $2.13 294 828
Aug 17, 2022 $2.17 $2.27 $2.08 $2.09 349 176
Click to get the best stock tips daily for free!

About Adaptimmune Therapeutics plc

Adaptimmune Therapeutics plc Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, focuses on providing novel cell therapies primarily to patients with solid tumors in the United States and the United Kingdom. The company's specific peptide enhanced affinity receptor (SPEAR) T-cell platform enables it to identify cancer targets. It is developing ADP-A2M4 that is in phase II clinical trials with SPEARHEAD-1 for synovial sarcoma and myxoid round cell liposa... ADAP Profile

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE

ROCKIT